{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:27:57Z","timestamp":1790015277678,"version":"4.0.1"},"reference-count":98,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pusan National University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>NF2-related schwannomatosis (NF2) is a genetic syndrome characterized by the growth of benign tumors in the nervous system, particularly bilateral vestibular schwannomas, meningiomas, and ependymomas. This review consolidates the current knowledge on NF2 syndrome, emphasizing the molecular pathology associated with the mutations in the gene of the same name, the NF2 gene, and the subsequent dysfunction of its product, the Merlin protein. Merlin, a tumor suppressor, integrates multiple signaling pathways that regulate cell contact, proliferation, and motility, thereby influencing tumor growth. The loss of Merlin disrupts these pathways, leading to tumorigenesis. We discuss the roles of another two proteins potentially associated with NF2 deficiency as well as Merlin: Yes-associated protein 1 (YAP), which may promote tumor growth, and Raf kinase inhibitory protein (RKIP), which appears to suppress tumor development. Additionally, this review discusses the efficacy of various treatments, such as molecular therapies that target specific pathways or inhibit neomorphic protein\u2013protein interaction caused by NF2 deficiency. This overview not only expands on the fundamental understanding of NF2 pathophysiology but also explores the potential of novel therapeutic targets that affect the clinical approach to NF2 syndrome.<\/jats:p>","DOI":"10.3390\/ijms25126558","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T08:52:10Z","timestamp":1718355130000},"page":"6558","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6866-7248","authenticated-orcid":false,"given":"Bae-Hoon","family":"Kim","sequence":"first","affiliation":[{"name":"Rare Disease R&D Center, PRG S&T Co., Ltd., Busan 46274, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9035-7932","authenticated-orcid":false,"given":"Yeon-Ho","family":"Chung","sequence":"additional","affiliation":[{"name":"Rare Disease R&D Center, PRG S&T Co., Ltd., Busan 46274, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Gyun","family":"Woo","sequence":"additional","affiliation":[{"name":"Rare Disease R&D Center, PRG S&T Co., Ltd., Busan 46274, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5717-7841","authenticated-orcid":false,"given":"So-mi","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, College of Natural Science, Pusan National University, Busan 46241, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyoung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, College of Natural Science, Pusan National University, Busan 46241, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minju","family":"Kim","sequence":"additional","affiliation":[{"name":"Rare Disease R&D Center, PRG S&T Co., Ltd., Busan 46274, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bum-Joon","family":"Park","sequence":"additional","affiliation":[{"name":"Rare Disease R&D Center, PRG S&T Co., Ltd., Busan 46274, Republic of Korea"},{"name":"Department of Molecular Biology, College of Natural Science, Pusan National University, Busan 46241, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/WNO.0000000000000675","article-title":"Neurofibromatosis Type 2-Related Eye Disease Correlated With Genetic Severity Type","volume":"39","author":"Painter","year":"2019","journal-title":"J. Neuroophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41431-021-01029-y","article-title":"Prevalence and natural history of schwannomas in neurofibromatosis type 2 (NF2): The influence of pathogenic variants","volume":"30","author":"Moualed","year":"2022","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jnnp-2018-318538","article-title":"Schwannomatosis: A genetic and epidemiological study","volume":"89","author":"Evans","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/GIM.0b013e3181ac9a27","article-title":"Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]","volume":"11","author":"Evans","year":"2009","journal-title":"Genet. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1101\/gad.1335605","article-title":"Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin","volume":"19","author":"McClatchey","year":"2005","journal-title":"Genes Dev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1177\/002215549904701113","article-title":"Expression of the neurofibromatosis type 2 gene in human tissues","volume":"47","author":"Vissers","year":"1999","journal-title":"J. Histochem. Cytochem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/brain\/awf115","article-title":"Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2","volume":"125","author":"Sperfeld","year":"2002","journal-title":"Brain"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2018.08.006","article-title":"Genetic Evaluation of Common Neurocutaneous Syndromes","volume":"89","year":"2018","journal-title":"Pediatr. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12964-020-00544-7","article-title":"Merlin regulates signaling events at the nexus of development and cancer","volume":"18","author":"Mota","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1086\/422700","article-title":"Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: A population-based study","volume":"75","author":"Baser","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s004390050255","article-title":"Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes","volume":"98","author":"Kluwe","year":"1996","journal-title":"Hum. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1399-0004.2009.01315.x","article-title":"Further genotype--phenotype correlations in neurofibromatosis 2","volume":"77","author":"Selvanathan","year":"2010","journal-title":"Clin. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-4-16","article-title":"Neurofibromatosis type 2 (NF2): A clinical and molecular review","volume":"4","author":"Evans","year":"2009","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1158\/1078-0432.CCR-17-0590","article-title":"Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders","volume":"23","author":"Evans","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7326\/0003-4819-113-1-39","article-title":"NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update","volume":"113","author":"Mulvihill","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jocn.2008.03.005","article-title":"Spinal tumors in neurofibromatosis-2: Management considerations\u2014A review","volume":"16","author":"Holland","year":"2009","journal-title":"J. Clin. Neurosci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nmeth.1280","article-title":"An empirical framework for binary interactome mapping","volume":"6","author":"Venkatesan","year":"2009","journal-title":"Nat. Methods"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/468851a","article-title":"Protein-protein interactions: Interactome under construction","volume":"468","author":"Bonetta","year":"2010","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00381-016-3226-8","article-title":"Early history of neurofibromatosis type 2 and related forms: Earliest descriptions of acoustic neuromas, medical curiosities, misconceptions, landmarks and the pioneers behind the eponyms","volume":"33","author":"Ruggieri","year":"2017","journal-title":"Childs Nerv. Syst."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00256-019-03290-1","article-title":"Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis","volume":"49","author":"Ahlawat","year":"2020","journal-title":"Skelet. Radiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/014556139907800208","article-title":"Neurofibromatosis type 2: Genetic and clinical features","volume":"78","author":"Evans","year":"1999","journal-title":"Ear Nose Throat J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s40136-014-0067-4","article-title":"Current Concepts in Management of Vestibular Schwannomas in Neurofibromatosis Type 2","volume":"2","author":"Tysome","year":"2014","journal-title":"Curr. Otorhinolaryngol. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1158\/1535-7163.MCT-17-1210","article-title":"Loss of NF2 Induces TGF\u03b2 Receptor 1-mediated Noncanonical and Oncogenic TGF\u03b2 Signaling: Implication of the Therapeutic Effect of TGF\u03b2 Receptor 1 Inhibitor on NF2 Syndrome","volume":"17","author":"Cho","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/1541-7786.MCR-21-0373","article-title":"RKIP Induction Promotes Tumor Differentiation via SOX2 Degradation in NF2-Deficient Conditions","volume":"20","author":"Cho","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"ref_26","first-page":"vdaa153","article-title":"New developments in neurofibromatosis type 2 and vestibular schwannoma","volume":"3","author":"Ren","year":"2021","journal-title":"Neurooncol. Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1227\/neu.0000000000002202","article-title":"Surgical Management of Peripheral Nerve Pathology in Patients With Neurofibromatosis Type 2","volume":"92","author":"Peyre","year":"2023","journal-title":"Neurosurgery"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3349\/ymj.2016.57.4.817","article-title":"Hearing Restoration in Neurofibromatosis Type II Patients","volume":"57","author":"Lee","year":"2016","journal-title":"Yonsei Med. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12935-023-02940-8","article-title":"The genetic landscape and possible therapeutics of neurofibromatosis type 2","volume":"23","author":"Ghalavand","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1016\/j.febslet.2014.04.001","article-title":"Molecular insights into NF2\/Merlin tumor suppressor function","volume":"588","author":"Cooper","year":"2014","journal-title":"FEBS Lett."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ncb1339","article-title":"The tumour-suppressor genes NF2\/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis","volume":"8","author":"Hamaratoglu","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1534-5807(01)00009-0","article-title":"The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling","volume":"1","author":"Shaw","year":"2001","journal-title":"Dev. Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1097-2765(03)00382-4","article-title":"Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1","volume":"12","author":"Kissil","year":"2003","journal-title":"Mol. Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1083\/jcb.200703010","article-title":"Contact-dependent inhibition of EGFR signaling by Nf2\/Merlin","volume":"177","author":"Curto","year":"2007","journal-title":"J. Cell Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.devcel.2010.10.008","article-title":"The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex","volume":"19","author":"Gladden","year":"2010","journal-title":"Dev. Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ccr.2014.05.001","article-title":"Merlin\/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus","volume":"26","author":"Li","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ccr.2011.02.017","article-title":"A tight junction-associated Merlin-angiomotin complex mediates Merlin\u2019s regulation of mitogenic signaling and tumor suppressive functions","volume":"19","author":"Yi","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1038\/onc.2013.438","article-title":"Merlin sumoylation is required for its tumor suppressor activity","volume":"33","author":"Qi","year":"2014","journal-title":"Oncogene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature04856","article-title":"Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase","volume":"442","author":"Jin","year":"2006","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbrc.2017.09.077","article-title":"The conformation change and tumor suppressor role of Merlin are both independent of Serine 518 phosphorylation","volume":"493","author":"Xing","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1038\/s41388-019-0883-6","article-title":"The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling","volume":"38","author":"Cui","year":"2019","journal-title":"Oncogene"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nrc2070","article-title":"The Salvador-Warts-Hippo pathway\u2014An emerging tumour-suppressor network","volume":"7","author":"Harvey","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1593\/neo.08642","article-title":"The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP","volume":"10","author":"Striedinger","year":"2008","journal-title":"Neoplasia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1242\/dev.096537","article-title":"Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap\/Taz transcriptional coactivators","volume":"140","author":"Lavado","year":"2013","journal-title":"Development"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/NEN.0000000000000211","article-title":"Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness","volume":"74","author":"Tanahashi","year":"2015","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1158\/2159-8290.CD-15-0330","article-title":"NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition","volume":"5","author":"Untch","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.devcel.2019.04.014","article-title":"YAP\/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells","volume":"49","author":"White","year":"2019","journal-title":"Dev. Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"109596","DOI":"10.1016\/j.celrep.2021.109596","article-title":"Stabilization of Motin family proteins in NF2-deficient cells prevents full activation of YAP\/TAZ and rapid tumorigenesis","volume":"36","author":"Wang","year":"2021","journal-title":"Cell Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10555-012-9365-9","article-title":"Raf kinase inhibitor protein (RKIP) in cancer","volume":"31","author":"Yeung","year":"2012","journal-title":"Cancer Metastasis Rev."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Yesilkanal, A.E., and Rosner, M.R. (2018). Targeting Raf Kinase Inhibitory Protein Regulation and Function. Cancers, 10.","DOI":"10.3390\/cancers10090306"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zaravinos, A., Bonavida, B., Chatzaki, E., and Baritaki, S. (2018). RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact. Cancers, 10.","DOI":"10.3390\/cancers10090287"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.1158\/1078-0432.CCR-05-0283","article-title":"Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis","volume":"11","author":"Hagan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1038\/emboj.2011.312","article-title":"Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer","volume":"30","author":"Yun","year":"2011","journal-title":"EMBO J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/1541-7786.MCR-08-0093","article-title":"Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer","volume":"6","author":"Li","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/emboj.2008.294","article-title":"Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7","volume":"28","author":"Yun","year":"2009","journal-title":"EMBO J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.canlet.2010.08.012","article-title":"Raf kinase inhibitor protein suppresses nuclear factor-\u03baB-dependent cancer cell invasion through negative regulation of matrix metalloproteinase expression","volume":"299","author":"Beshir","year":"2010","journal-title":"Cancer Lett."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Figy, C., Guo, A., Fernando, V.R., Furuta, S., Al-Mulla, F., and Yeung, K.C. (2023). Changes in Expression of Tumor Suppressor Gene RKIP Impact How Cancers Interact with Their Complex Environment. Cancers, 15.","DOI":"10.3390\/cancers15030958"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1053\/j.gastro.2006.07.012","article-title":"Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells","volume":"131","author":"Lee","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00432-018-2672-y","article-title":"Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines","volume":"144","author":"Kim","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.iliver.2022.11.005","article-title":"Effects of Raf kinase inhibitor protein on biological characteristics of hepatocellular carcinoma cells and its potential therapeutic effects","volume":"1","author":"Zhang","year":"2022","journal-title":"iLIVER"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bbrc.2012.07.025","article-title":"MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells","volume":"425","author":"Huang","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.abb.2016.09.007","article-title":"RKIP suppresses the proliferation and metastasis of breast cancer cell lines through up-regulation of miR-185 targeting HMGA2","volume":"610","author":"Zou","year":"2016","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s00432-016-2206-4","article-title":"Effects of Raf kinase inhibitor protein expression on pancreatic cancer cell growth and motility: An in vivo and in vitro study","volume":"142","author":"Dai","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.18632\/oncotarget.3543","article-title":"NF2 blocks Snail-mediated p53 suppression in mesothelioma","volume":"6","author":"Cho","year":"2015","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Chow, H.Y., Stepanova, D., Koch, J., and Chernoff, J. (2010). p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013791"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.18632\/oncotarget.2810","article-title":"Group I Paks as therapeutic targets in NF2-deficient meningioma","volume":"6","author":"Chow","year":"2015","journal-title":"Oncotarget"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cell.2010.01.029","article-title":"Merlin\/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus","volume":"140","author":"Li","year":"2010","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1158\/1535-7163.MCT-16-0821","article-title":"Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis","volume":"16","author":"Cooper","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.21037\/jtd.2017.09.34","article-title":"Essential signaling in NF2 loss-related tumours: The therapeutic potential of CRL4(DCAF1) and mTOR combined inhibition","volume":"9","author":"Yang","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Chang, L.S., Oblinger, J.L., Smith, A.E., Ferrer, M., Angus, S.P., Hawley, E., Petrilli, A.M., Beauchamp, R.L., Riecken, L.B., and Erdin, S. (2021). Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0252048"},{"key":"ref_72","first-page":"471","article-title":"A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2","volume":"6","author":"Petrilli","year":"2014","journal-title":"Am. J. Transl. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"890","DOI":"10.18632\/oncotarget.28254","article-title":"CUDC907, a dual phosphoinositide-3 kinase\/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells","volume":"13","author":"Huegel","year":"2022","journal-title":"Oncotarget"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1158\/0008-5472.CAN-16-2834","article-title":"An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis","volume":"77","author":"Stepanova","year":"2017","journal-title":"Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"126","DOI":"10.18632\/oncoscience.417","article-title":"A new concept in NF2 pharmacotherapy: Targeting fatty acid synthesis","volume":"5","author":"Stepanova","year":"2018","journal-title":"Oncoscience"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: Basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/B978-0-444-52902-2.00054-0","article-title":"Chapter 54\u2014Neurofibromatosis type 2 (NF2): Diagnosis and management","volume":"Volume 115","author":"Said","year":"2013","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/CCO.0000000000000579","article-title":"Neurofibromatosis type 2 and related disorders","volume":"31","author":"Halliday","year":"2019","journal-title":"Curr. Opin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","article-title":"Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas","volume":"34","author":"Blakeley","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1200\/JCO.19.01367","article-title":"Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma","volume":"37","author":"Plotkin","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/annonc\/mdq566","article-title":"Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: Sustain under continuous drug application and rebound after drug discontinuation","volume":"21","author":"Mautner","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11060-016-2276-9","article-title":"Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort","volume":"131","author":"Morris","year":"2017","journal-title":"J. Neurooncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","article-title":"Resistance to targeted therapy in renal-cell carcinoma","volume":"10","author":"Rini","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5306\/wjco.v13.i1.1","article-title":"Update on the treatment of metastatic renal cell carcinoma","volume":"13","year":"2022","journal-title":"World J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"iii419","DOI":"10.1093\/neuonc\/noaa222.612","article-title":"Nfb-08. Phase Ii Study of Axitinib in Patients with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas","volume":"22","author":"Phadnis","year":"2020","journal-title":"Neuro Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/13543784.2017.1351543","article-title":"Selumetinib for the treatment of non-small cell lung cancer","volume":"26","author":"Casaluce","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in Children with Inoperable Plexiform Neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/neuonc\/nor072","article-title":"AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas","volume":"13","author":"Bush","year":"2011","journal-title":"Neuro Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1158\/0008-5472.CAN-12-1888","article-title":"Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth","volume":"73","author":"Burns","year":"2013","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/lio2.643","article-title":"Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas","volume":"6","author":"Welling","year":"2021","journal-title":"Laryngoscope Investig. Otolaryngol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1517\/14656566.2012.688029","article-title":"Crizotinib in the treatment of non-small-cell lung cancer","volume":"13","author":"Forde","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/2278-330X.110506","article-title":"Crizotinib: A comprehensive review","volume":"2","author":"Sahu","year":"2013","journal-title":"South Asian J. Cancer"},{"key":"ref_96","first-page":"91","article-title":"Clinical use of crizotinib for the treatment of non-small cell lung cancer","volume":"7","author":"Roberts","year":"2013","journal-title":"Biologics"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2015.01.049","article-title":"Practical management of anticoagulation in patients with atrial fibrillation","volume":"65","author":"Kovacs","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2018.36.15_suppl.3031","article-title":"Association of TGF-\u03b2 responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-\u03b2 receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors","volume":"36","author":"Keedy","year":"2018","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/12\/6558\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:58:34Z","timestamp":1760108314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/12\/6558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":98,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["ijms25126558"],"URL":"https:\/\/doi.org\/10.3390\/ijms25126558","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]}}}